Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and immunogenicity of different liponanaoparticle (LNP) formulations of modified ribonucleic acid (mRNA) vaccines using the RSV pre-F antigen in hea...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Sanofi
NCT07164430 · Respiratory Syncytial Virus (RSV) Infection, Respiratory Syncytial Virus Hospitalizations, and more
NCT05639894 · Respiratory Syncytial Virus Immunization
Site # 0361003
Wollongong, New South Wales
Site # 0361006
Brisbane, Queensland
Site # 0361005
Morayfield, Queensland
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions